Protara Therapeutics Inc

Company Profile

Protara Therapeutics Inc had its IPO on 2014-10-22 under the ticker symbol TARA.

The company operates in the Healthcare sector and Biotechnology industry. Protara Therapeutics Inc has a staff strength of 25 employees.

Stock update

Shares of Protara Therapeutics Inc opened at $2.18 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $2.12 - $2.2, and closed at $2.12.

This is a 0% increase from the previous day's closing price.

A total volume of 6,293 shares were traded at the close of the day’s session.

In the last one week, shares of Protara Therapeutics Inc have slipped by -2.75%.

Protara Therapeutics Inc's Key Ratios

Protara Therapeutics Inc has a market cap of $24.70 million, indicating a price to book ratio of 0.2413 and a price to sales ratio of 0.

In the last 12-months Protara Therapeutics Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-39544000. The EBITDA ratio measures Protara Therapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Protara Therapeutics Inc’s operating margin was 0% while its return on assets stood at -19.92% with a return of equity of -58.09%.

In Q2, Protara Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Protara Therapeutics Inc’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-5.92 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Protara Therapeutics Inc’s profitability.

Protara Therapeutics Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 1.5954. Its price to sales ratio in the trailing 12-months stood at 0.

Protara Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$95.14 million

Total Liabilities

$4.93 million

Operating Cash Flow

$0

Capital Expenditure

$2000

Dividend Payout Ratio

0%

Protara Therapeutics Inc ended 2024 with $95.14 million in total assets and $0 in total liabilities. Its intangible assets were valued at $95.14 million while shareholder equity stood at $85.23 million.

Protara Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $4.93 million in other current liabilities, 11000.00 in common stock, $-180303000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $33.98 million and cash and short-term investments were $80.36 million. The company’s total short-term debt was $949,000 while long-term debt stood at $0.

Protara Therapeutics Inc’s total current assets stands at $84.27 million while long-term investments were $0.00 and short-term investments were $46.38 million. Its net receivables were $344000.00 compared to accounts payable of $1.85 million and inventory worth $3.56 million.

In 2024, Protara Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $2000.

Comparatively, Protara Therapeutics Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$2.12

52-Week High

$4.429

52-Week Low

$2.1

Analyst Target Price

$31.4

Protara Therapeutics Inc stock is currently trading at $2.12 per share. It touched a 52-week high of $4.429 and a 52-week low of $4.429. Analysts tracking the stock have a 12-month average target price of $31.4.

Its 50-day moving average was $2.42 and 200-day moving average was $2.96 The short ratio stood at 1.3 indicating a short percent outstanding of 0%.

Around 1598.9% of the company’s stock are held by insiders while 5177.5% are held by institutions.